BeOne Medicines (ONC) – Analysts’ Recent Ratings Updates

BeOne Medicines (NASDAQ: ONC) has recently received a number of price target changes and ratings updates:

• 5/15/2026 – BeOne Medicines had its price target raised by Leerink Partners from $364.00 to $367.00. They now have an “outperform” rating on the stock.
• 5/9/2026 – BeOne Medicines was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 5/7/2026 – BeOne Medicines had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $395.00 price target on the stock.
• 5/7/2026 – BeOne Medicines had its price target raised by Guggenheim from $410.00 to $420.00. They now have a “buy” rating on the stock.
• 5/7/2026 – BeOne Medicines had its price target raised by Barclays PLC from $405.00 to $409.00. They now have an “overweight” rating on the stock.
• 5/7/2026 – BeOne Medicines had its price target raised by Royal Bank Of Canada from $423.00 to $425.00. They now have an “outperform” rating on the stock.
• 5/7/2026 – BeOne Medicines had its “buy” rating reaffirmed by Truist Financial Corporation. They now have a $413.00 price target on the stock, up from $411.00.
• 5/4/2026 – BeOne Medicines is now covered by Wells Fargo & Company. They set an “overweight” rating and a $400.00 price target on the stock.
• 5/4/2026 – BeOne Medicines was upgraded by Wells Fargo & Company to “strong-buy”.
• 4/20/2026 – BeOne Medicines had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 3/27/2026 – BeOne Medicines is now covered by Wolfe Research. They set an “outperform” rating and a $340.00 price target on the stock.

Insider Buying and Selling at BeOne Medicines

In other news, SVP Chan Henry Lee sold 341 shares of the firm’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $300.00, for a total transaction of $102,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders have sold 1,005 shares of company stock worth $308,907. Company insiders own 6.19% of the company’s stock.

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.